Analytical Data
-
Gene name
omp25
- Application
-
Alternative Names
omp25; BruAb1_0720; 25 kDa outer-membrane immunogenic protein
-
Species
strain 9-941
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q44664
-
Expression Region
24-213aa
-
Molecular Weight
27.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OMP25, an outer membrane protein derived from *Neisseria gonorrhoeae*, has garnered significant attention in the field of molecular microbiology and vaccine development due to its potential role in bacterial pathogenesis and immune response modulation. Recognized for its ability to elicit antibodies, OMP25 is believed to facilitate bacterial adherence and invasion, making it a crucial target for therapeutic interventions. Researchers have focused on the recombinant expression of OMP25 to assess its immunogenic properties and explore its efficacy as a subunit vaccine candidate against gonorrhea. Given the increasing global prevalence of antibiotic-resistant *Neisseria gonorrhoeae*, the urgent need for novel preventive strategies underscores the importance of studying OMP25. The recombinant protein facilitates detailed investigations into antigenic variation and cellular interactions, enhancing our understanding of the immune mechanisms involved in infection. Furthermore, the exploration of OMP25's potential as a vaccine component could contribute to the development of effective immunization strategies, ultimately aiming to reduce the incidence of gonorrhea and improve public health outcomes. Thus, the comprehensive study of OMP25 not only sheds light on its biological significance but also holds promise for innovative approaches in combating this prevalent sexually transmitted infection.
